Literature DB >> 1334142

Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours.

N R Lemoine1, C M Hughes, J K Cowell.   

Abstract

A series of 34 Wilms' tumours have been analysed for abnormal expression of the tumour suppressor gene p53 using frozen section immunohistochemistry. All tumours showed immunoreactivity with at least one of the specific antibodies used (monoclonal antibody PAb240, polyclonal antibodies CM1 and JG8). Abnormalities of p53 expression are very frequent in this type of childhood tumour.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334142     DOI: 10.1002/path.1711680213

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

1.  Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.

Authors:  C Lahoti; P Thorner; D Malkin; H Yeger
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

2.  Apoptotic protein expression in favorable-histology Wilms tumor correlates with tumor recurrence.

Authors:  Shipra Agarwal; Venkateswaran K Iyer; Sandeep Agarwala; Sandeep R Mathur; Manju Aron; S Datta Gupta; Kusum Verma
Journal:  Pediatr Surg Int       Date:  2010-10-21       Impact factor: 1.827

3.  p53 protein expression in nephroblastomas: a predictor of poor prognosis.

Authors:  D Govender; P Harilal; G P Hadley; R Chetty
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

Review 4.  The yin and yang of kidney development and Wilms' tumors.

Authors:  Peter Hohenstein; Kathy Pritchard-Jones; Jocelyn Charlton
Journal:  Genes Dev       Date:  2015-03-01       Impact factor: 11.361

5.  The association of miR34b/c and TP53 gene polymorphisms with Wilms tumor risk in Chinese children.

Authors:  Juxiang Wang; Susu Lou; Xiaokai Huang; Yixiao Mo; Zhen Wang; Jinhong Zhu; Xiaoqian Tian; Jiandong Shi; Haixia Zhou; Jing He; Jichen Ruan
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.